Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer

Tumor Biology

Volumn 39, Issue 4, 2017, Pages

  Kumari, Nitu ^a,b   Agrawal, Usha ^a,c   Mishra, Ashwani Kumar ^d   Kumar, Anup ^e   Vasudeva, Pawan ^e   Mohanty, Nayan Kumar ^f   Saxena, Sunita ^a  

^a SAFDARJUNG HOSPITAL CAMPUS   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c SYMBIOSIS INTERNATIONAL UNIVERSITY   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e SAFDARJUNG HOSPITAL   (India)

^f Saket City Hospital   (India)

Author keywords

bladder cancer; cytokines; Immune response; non invasive marker

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLATELET DERIVED GROWTH FACTOR; RANTES; VASCULOTROPIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CD4 CD8 RATIO; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; TUMOR INVASION; URINALYSIS; BLADDER TUMOR; BLOOD; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; TUMOR RECURRENCE; URINE;

ADULT; AGED; CYTOKINES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 85017481365     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317697552     Document Type: Article

References (27)

1. Agarwal A, Agrawal U, Verma S. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 2010; 32(2): 348–356.
2. Agarwal A, Verma S, Burra U. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 2006; 55(6): 734–743.
3. Anastasiadis A, de Reijke TM., Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012; 4(1): 13–32.
4. Fridman WH, Pagès F, Sautès-Fridman C. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12(4): 298–306.
5. Terrando N, Monaco C, Ma D. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A 2010; 107(47): 20518–20522.
6. Balkwill F., Cancer and the chemokine network. Nat Rev Cancer 2004; 4(7): 540–550.
7. Dunn GP, Bruce AT, Ikeda H. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3(11): 991–998.
8. Dehqanzada ZA, Storrer CE, Hueman MT. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep 2007; 17(3): 687–694.
9. Enewold L, Mechanic LE, Bowman ED. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009; 18(1): 215–222.
10. Błogowski W, Deskur A, Budkowska M. Selected cytokines in patients with pancreatic cancer: a preliminary report. PLoS ONE 2014; 9(5): e97613.
11. Gonzalez EJ, Arms L, Vizzard MA., The role(s) of cytokines/chemokines in urinary bladder inflammation and dysfunction. Biomed Res Int 2014; 2014: 120525.
12. Rodhe N, Löfgren S, Strindhall J. Cytokines in urine in elderly subjects with acute cystitis and asymptomatic bacteriuria. Scand J Prim Health Care 2009; 27: 74–79.
13. Peng CH, Jhang JF, Shie JH. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis – clinical results and immunohistochemistry analysis. Urology 2013; 82(6): 1452.e1–1452.e6.
14. Niedźwiecki S, Stępień T, Kuzdak K. Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbecks Arch Surg 2008; 393(3): 275–280.
15. Arend WP, Evans CH., IL1 receptor antagonist [IL-IF3]. In: Thomson AW, Lotze MT, (eds) The cytokine handbook. Volume 1. 4th ed. San Diego, CA: Academic Press, 2003, pp. 735–745.
16. Jain S, Gautam V, Naseem S., Acute-phase proteins: as diagnostic tool. J Pharm Bioallied Sci 2011; 3(1): 118.
17. Nazha B, Moussaly E, Zaarour M. Hypoalbuminemia in colorectal cancer prognosis: nutritional marker or inflammatory surrogate? World J Gastrointest Surg 2015; 7(12): 370.
18. Goldstein R, Hanley C, Morris J. Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer. Cancer 2011; 3(4): 4281–4293.
19. Perng P, Lim M., Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front Oncol 2015; 5: 153.
20. Seo Y, Baba H, Fukuda T. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88(10): 2239–2245.
21. Perrot-Applanat M, Di Benedetto M., Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell Adh Migr 2012; 6(6): 547–553.
22. Roberts E, Cossigny DAF, Quan GM., The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer 2013; 2013: 418340.
23. Urquidi V, Chang M, Dai Y. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol 2012; 12(1): 12.
24. Burnier A, Shimizu Y, Dai Y. CXCL1 is elevated in the urine of bladder cancer patients. Springerplus 2015; 4(1): 610.
25. Gotsch F, Romero R, Friel L. CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med 2007; 20(11): 777–792.
26. Liu M, Guo S, Stiles JK., The emerging role of CXCL10 in cancer (Review). Oncol Lett 2011; 2(4): 583–589.
27. Burkholder B, Huang RY, Burgess R. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 2014; 1845(2): 182–201.